Increasing evidence indicates that DUX4 causes widespread mis-regulation of signaling pathways (36, 41, 44, 52–55), making these cascades important potential targets for FSHD therapeutics. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.